Christopher Causey Sells 2,240 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Christopher Causey sold 2,240 shares of the business's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now directly owns 4,185 shares in the company, valued at $1,087,723.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $1.89 on Monday, reaching $260.51. 587,222 shares of the stock were exchanged, compared to its average volume of 461,113. The firm's 50 day moving average is $236.86 and its 200-day moving average is $229.35. United Therapeutics Co. has a one year low of $204.44 and a one year high of $264.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The firm has a market cap of $11.56 billion, a PE ratio of 12.41 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts' consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm's quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.86 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 23.88 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. raised its stake in shares of United Therapeutics by 9.0% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 1,705 shares of the biotechnology company's stock valued at $385,000 after acquiring an additional 141 shares during the last quarter. Raymond James & Associates boosted its stake in United Therapeutics by 1.7% during the third quarter. Raymond James & Associates now owns 28,054 shares of the biotechnology company's stock worth $6,337,000 after acquiring an additional 471 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in United Therapeutics by 48.8% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 2,345 shares of the biotechnology company's stock worth $530,000 after purchasing an additional 769 shares during the period. Advisor Partners II LLC grew its holdings in United Therapeutics by 7.7% in the third quarter. Advisor Partners II LLC now owns 1,339 shares of the biotechnology company's stock worth $302,000 after purchasing an additional 96 shares during the period. Finally, Park Avenue Securities LLC bought a new stake in United Therapeutics in the third quarter valued at $303,000. Institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on UTHR. Wedbush reissued an "outperform" rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, April 11th. The Goldman Sachs Group upped their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the company a "neutral" rating in a report on Friday. Wells Fargo & Company upped their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Finally, SVB Leerink assumed coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an "outperform" rating and a $330.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $308.78.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.